Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DYRK1A | Q13627 | 2/20 | 0.51 |
| ▸ | DYRK1B | Q9Y463 | 2/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 8/20 | 0.46 |
| ▸ | MAPK3 | P27361 | 6/20 | 0.46 |
| ▸ | ROCK2 | O75116 | 2/20 | 0.46 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.46 |
| ▸ | F10 | P00742 | 1/20 | 0.42 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10324847 | 1.00 | DYRK1A (0.51) | DYRK1ADYRK1BLMNASMN1; SMN2KDM4E | |
| SCHEMBL10322492 | 0.91 | ROCK2 (0.52) | DYRK1ALMNASMN1; SMN2KDM4EMAPK1 | |
| SCHEMBL10323131 | 0.91 | ROCK2 (0.52) | DYRK1ALMNASMN1; SMN2KDM4EMAPK1 | |
| SCHEMBL10324928 | 0.91 | ROCK2 (0.52) | DYRK1ALMNASMN1; SMN2KDM4EMAPK1 | |
| SCHEMBL10321531 | 0.89 | DYRK1A (0.51) | DYRK1ADYRK1BLMNASMN1; SMN2KDM4E | |
| SCHEMBL10322648 | 0.89 | DYRK1A (0.47) | DYRK1ADYRK1BMAPK1MAPK3ROCK2 | |
| SCHEMBL10322409 | 0.87 | UTS2R (0.57) | — | |
| SCHEMBL10322147 | 0.86 | DYRK1A (0.51) | DYRK1ADYRK1BMAPK1MAPK3ROCK2 | |
| SCHEMBL10324846 | 0.86 | DYRK1A (0.51) | DYRK1ADYRK1BMAPK1MAPK3ROCK2 | |
| SCHEMBL10324549 | 0.82 | ROCK1 (0.56) | LMNASMN1; SMN2KDM4EROCK2ROCK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120184542-A1 | PYRIDO PYRIMIDINES | ANDERSON KEVIN (US) | 2012-07-19 | — | — | US | claimed |
| US-20120184562-A1 | 1,6- AND 1,8-NAPHTHYRIDINES | LUK KIN-CHUN (US) | 2012-07-19 | — | — | US | claimed |
| US-20120184542-A1 | PYRIDO PYRIMIDINES | ANDERSON KEVIN (US) | 2012-07-19 | — | — | US | disclosed |
| US-20120184562-A1 | 1,6- AND 1,8-NAPHTHYRIDINES | LUK KIN-CHUN (US) | 2012-07-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120184542-A1 | PYRIDO PYRIMIDINES | TYMS, TYMP, DPYD | DYRK1A 654/4885DYRK1B 570/4885LMNA 1119/4885 |
| US-20120184562-A1 | 1,6- AND 1,8-NAPHTHYRIDINES | PSEN1, BRCA1, PSEN2 | DYRK1A 1366/4885DYRK1B 2109/4885LMNA 182/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.